This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pricing, Demand Up International Flavors (IFF) Despite Cost Woes
by Zacks Equity Research
Pricing actions, productivity initiatives, and investment in growth and acquisitions remain key drivers for International Flavors (IFF) despite inflationary cost pressures.
International Flavors (IFF) Q2 Earnings & Sales Top Estimates
by Zacks Equity Research
International Flavors' (IFF) Q2 top line gains from solid growth in Nourish and Pharma Solutions.
International Flavors (IFF) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
International Flavors (IFF) delivered earnings and revenue surprises of 8.45% and 1.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for International Flavors' (IFF) Q2 Earnings?
by Zacks Equity Research
International Flavors' (IFF) Q2 performance is likely to reflect benefits from robust demand for home care and personal categories, while escalating costs might have been a spoilsport.
Pricing Actions, Acquisitions to Aid International Flavors (IFF)
by Zacks Equity Research
Strong demand, pricing actions, productivity initiatives and investment in growth and acquisitions remain key growth drivers for International Flavors (IFF).
Why Is Grocery Outlet Holding Corp. (GO) Up 5.2% Since Last Earnings Report?
by Zacks Equity Research
Grocery Outlet Holding Corp. (GO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
International Flavors (IFF) Q1 Earnings Top Estimates, View Up
by Zacks Equity Research
International Flavors' (IFF) Q1 top line gains from solid growth in Health & Biosciences, Nourish and Pharma Solutions and additional sales related to the merger with N&B business.
International Flavors (IFF) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
International Flavors (IFF) delivered earnings and revenue surprises of 29.01% and 1.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for International Flavors' (IFF) Q1 Earnings?
by Zacks Equity Research
International Flavors' (IFF) Q1 performance is likely to reflect benefits from robust demand for home care and personal categories, while escalating costs might have been a spoilsport.
Earnings Preview: International Flavors (IFF) Q1 Earnings Expected to Decline
by Zacks Equity Research
International Flavors (IFF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
International Flavors (IFF) Closes Health Wright Products Buyout
by Zacks Equity Research
International Flavors' (IFF) latest buyout provides formulation and finished format capabilities to Health & Biosciences probiotics, natural extracts and botanicals businesses.
International Flavors (IFF) Bets on Strong Demand Amid High Costs
by Zacks Equity Research
Strong demand, productivity initiatives, investment in growth and acquisitions remain key growth drivers for International Flavors & Fragrances (IFF). Inflated costs might play spoilsport for the time being.
International Flavors (IFF) Down 11.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
International Flavors (IFF) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Schwab U.S. MidCap ETF (SCHM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHM
DuPont (DD) Inks Deal to Divest Mobility & Materials for $11B
by Zacks Equity Research
DuPont's (DD) latest deal strengthens its foothold in the fields of electronics, water, industrial technologies, protection and next-gen automotive.
International Flavors' (IFF) Q4 Earnings & Sales Beat Estimates
by Zacks Equity Research
International Flavors' (IFF) Q4 top line gains from solid growth in Health & Biosciences and Nourish, Pharma Solutions & Scent and additional sales related to the merger with N&B business.
International Flavors (IFF) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
International Flavors (IFF) delivered earnings and revenue surprises of 5.77% and 2.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for International Flavors' (IFF) Q4 Earnings?
by Zacks Equity Research
International Flavors' (IFF) Q4 results are likely to reflect benefits from robust demand for home care and personal categories, while high costs might have been a spoilsport.
Earnings Preview: International Flavors (IFF) Q4 Earnings Expected to Decline
by Zacks Equity Research
International Flavors (IFF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Schwab U.S. MidCap ETF (SCHM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHM
New Strong Sell Stocks for November 15th
by Zacks Equity Research
ARDS, CNNE, EXK, GP, and IFF have been added to the Zacks Rank #5 (Strong Sell) List on November 15, 2021.
International Flavors (IFF) Beats on Q3 Earnings & Sales, Up Y/Y
by Zacks Equity Research
International Flavors' (IFF) Q3 top line reflects benefits from solid growth in Nourish, Scent and Health & Biosciences as well as additional sales related to the merger with N&B business.
International Flavors (IFF) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
International Flavors (IFF) delivered earnings and revenue surprises of 5.76% and 1.77%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Is Invesco S&P 500 Equal Weight Materials ETF (RTM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RTM
What's in the Cards for International Flavors' (IFF) Q3 Earnings?
by Zacks Equity Research
International Flavors' (IFF) Q3 results likely to reflect benefits from robust demand for home care and personal categories, while high raw-material costs might have been a spoilsport.